SAB Biotherapeutics (SABS) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$0.21.
- SAB Biotherapeutics' EPS (Weighted Average and Diluted) rose 8125.0% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.09, marking a year-over-year increase of 5095.24%. This contributed to the annual value of -$3.68 for FY2024, which is 5180.21% up from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' EPS (Weighted Average and Diluted) is -$0.21, which was up 8125.0% from -$1.09 recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' EPS (Weighted Average and Diluted) peaked at $0.05 during Q1 2021, and registered a low of -$3.85 during Q4 2023.
- For the 5-year period, SAB Biotherapeutics' EPS (Weighted Average and Diluted) averaged around -$0.84, with its median value being -$0.56 (2025).
- As far as peak fluctuations go, SAB Biotherapeutics' EPS (Weighted Average and Diluted) crashed by 740000.0% in 2023, and later skyrocketed by 8125.0% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$0.41 in 2021, then plummeted by 341.27% to -$1.81 in 2022, then plummeted by 112.8% to -$3.85 in 2023, then surged by 68.04% to -$1.23 in 2024, then skyrocketed by 82.93% to -$0.21 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.21 in Q3 2025, compared to -$1.09 in Q2 2025 and -$0.56 in Q1 2025.